<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRPO</journal-id><journal-title-group><journal-title>Asian Case Reports in Oncology</journal-title></journal-title-group><issn pub-type="epub">2169-8821</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRPO.2015.43004</article-id><article-id pub-id-type="publisher-id">ACRPO-16048</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRPO20150300000_62291106.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  1例晚期胃癌患者的循证治疗
  Evidence-Based Treatment for 1 Case with Advanced Gastric Cancer Patients
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>江</surname><given-names>平</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>崇高</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>昇庠</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>增岭</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>伟</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>桂</surname><given-names>德春</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>南京市浦口区中心医院普通外科，江苏 南京</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>jiangping04@163.com(江平)</email>;<email>wangchonggao007@sina.com(王崇)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>09</month><year>2015</year></pub-date><volume>04</volume><issue>03</issue><fpage>20</fpage><lpage>25</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：采用循证医学方法为1例晚期胃癌患者制定诊治方案。方法：根据临床问题检索MEDLINE、ACP Journal Club、中国知网，并利用搜索引擎——谷歌学术搜索在互联网所获取的文献进行归纳分析。结果：共获得有关晚期胃癌姑息手术和新辅助化疗时机的系统评价6篇，临床对照研究病例756例。以上证据表明：晚期胃癌行新辅助化疗的根治性手术率及生存率优于姑息手术组。结合客观证据及患者意愿，为患者实施了两个疗程的奥沙利铂+希罗达(Cape + OX)化疗方案，结合化疗前后病灶的影像学变化，成功实施了手术，无手术后并发症发生。结论：循征医学方法对疑难病例的治疗有一定的指导作用。 Objective: To make the diagnosis and treatment for advanced gastric cancer patients using evi-dence-based medicine method. Methods: Retrievalling MEDLINE, ACP Journal Club, Chinese How-Net according to the clinical question, and then searching and summarizing the literature in Internet using the search engines—Google academic search. Results: 6 systematic reviews about advanced gastric cancer palliative operation and neoadjuvant chemotherapy time and 756 cases of controlled clinical study were obtained. The above evidence approved that it was superior to palliative operation group in the radical surgery and survival rates. Combining the objective evidence and the patients’ willingness, patients were treated with two courses of chemotherapy options with oxaliplatin plus capecitabine (Cape + OX) regimen. The operation was performed successfully without complications combining with the change of focus images before and after chemotherapy. Conclusion: The evidence-based medicine method was useful for the treatment of difficult patients.
    
    
  
 
</p></abstract><kwd-group><kwd>胃癌，晚期，循证治疗, Gastric Cancer</kwd><kwd> Advanced</kwd><kwd> Evidence-Based Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1例晚期胃癌患者的循证治疗<sup> </sup></title><p>江平，王崇高<sup>*</sup>，胡昇庠，张增岭，胡伟，桂德春</p><p>南京市浦口区中心医院普通外科，江苏 南京</p><p>Email: jiangping04@163.com, <sup>*</sup>wangchonggao007@sina.com</p><p>收稿日期：2015年8月31日；录用日期：2015年9月14日；发布日期：2015年9月17日</p><disp-formula id="hanspub.16048-formula413"><graphic xlink:href="http://html.hanspub.org/file/2-2530032x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：采用循证医学方法为1例晚期胃癌患者制定诊治方案。方法：根据临床问题检索MEDLINE、ACP Journal Club、中国知网，并利用搜索引擎——谷歌学术搜索在互联网所获取的文献进行归纳分析。结果：共获得有关晚期胃癌姑息手术和新辅助化疗时机的系统评价6篇，临床对照研究病例756例。以上证据表明：晚期胃癌行新辅助化疗的根治性手术率及生存率优于姑息手术组。结合客观证据及患者意愿，为患者实施了两个疗程的奥沙利铂+希罗达(Cape + OX)化疗方案，结合化疗前后病灶的影像学变化，成功实施了手术，无手术后并发症发生。结论：循征医学方法对疑难病例的治疗有一定的指导作用。</p><p>关键词 :胃癌，晚期，循证治疗</p><disp-formula id="hanspub.16048-formula414"><graphic xlink:href="http://html.hanspub.org/file/2-2530032x7_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>晚期胃癌病人治疗较为棘手[<xref ref-type="bibr" rid="hanspub.16048-ref1">1</xref>] ，单一化疗、姑息性手术还是新辅助化疗后再进行手术临床上无明确定论[<xref ref-type="bibr" rid="hanspub.16048-ref2">2</xref>] 。理论上而言，胃癌的新辅助化疗结合根治性手术要优于姑息性手术及术后化疗。理论依据为：新辅助化疗可降低肿瘤的分期，从而提高手术完全切除率[<xref ref-type="bibr" rid="hanspub.16048-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.16048-ref4">4</xref>] ，同时新辅助化疗是最早阻止肿瘤细胞扩散方法，同时切除了原发病灶，从而减轻肿瘤负荷和降低肿瘤细胞扩散的可能性[<xref ref-type="bibr" rid="hanspub.16048-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.16048-ref6">6</xref>] 。笔者通过1例晚期胃癌患者的循证治疗，探讨晚期胃癌行新辅助化疗的疗效及价值。</p></sec><sec id="s4"><title>2. 病历资料</title><p>患者，78岁，女，因“上腹部疼痛不适两月余”于2012-09-28入院。患者两月余前无明显诱因出现上腹部疼痛不适，有吞咽哽噎感，无恶心，无呕吐，无畏寒发热，无黄疸。既往无特殊病史。查体：左锁骨上窝可及多枚大小约2.0 &#215; 1.0 cm、境界不清、与皮肤有粘连、无压痛的肿大淋巴结。腹部平坦，腹壁静脉无怒张，未见胃肠型及蠕动波，腹部压痛，无反跳痛，无肌紧张，Murphy’s征(一)，未及明显包块，肝脾肋下未及，肝区叩击痛阳性，移动性浊音阴性，肠鸣音正常。胃镜：贲门可见一大小约4 &#215; 3 cm溃疡型肿块，结合病理提示“贲门癌”。腹部增强CT提示：胃小弯近贲门部占位，腹主动脉周围淋巴结肿大。于2012-10-03在局部麻醉下行左颈部淋巴结活检术，手术后病理提示：左颈部淋巴结见腺癌成分，考虑左颈部淋巴结转移，该患者临床分期为晚期胃癌(胃癌IV期)。</p></sec><sec id="s5"><title>3. 治疗方案的选择问题</title><p>医生对于该患者的治疗方案存在分歧：1)患者颈部肿大淋巴结证实为转移癌，临床分期为晚期胃癌(胃癌IV期)，吞咽哽噎感明显，为解决可能出现的梗阻症状，可考虑行姑息性手术，减轻机体肿瘤负荷；2)结合患者为高龄，手术风险大，疗效差，姑息性手术治疗无必要，可考虑单一化疗；3)单一化疗可能产生多药耐药性，亦不能切除原发病灶和减轻肿瘤负荷，可考虑先行新辅助化疗，降低肿瘤分期，根据化疗效果决定是否可行手术治疗。为尽快获取高质量的证据指导治疗，按照PICO原则[<xref ref-type="bibr" rid="hanspub.16048-ref7">7</xref>] ，将医生的治疗分歧转化为问题：1)晚期胃癌患者姑息性手术还是根据新辅助化疗结果适时手术治疗；2)仅行单一化疗。</p></sec><sec id="s6"><title>4. 检索策略及结果</title><sec id="s6_1"><title>4.1. 检索资源</title><p>检索MEDLINE (1998年1月至2012年10月)，ACP journal club (2012年9月)及CNKI (1998年1月至2012年10月)，并利用搜索引擎——谷歌学术搜索(2012年10月)。首先根据检索词检索高质量的文献，然后由两名副主任医生根据一次检索结果根据是否有助于回答临床问题二次选定相关文献，对于有争议的二次文献证据，则参考临床指南、随机对照试验或其他综述。</p></sec><sec id="s6_2"><title>4.2. 检索词</title><p>所用检索词为检索词英文：neoadjuvant chemotherapy，preoperative chemotherapy，gastric cancer，advanced gastirc cancer，operation，palliative operation，meta-analysis等。中文：新辅助化疗，术前化疗，晚期胃癌，胃肿瘤，手术，姑息性手术，Meta分析等。</p></sec><sec id="s6_3"><title>4.3. 检索结果</title><p>检索MEDLINE (1998年1月至2012年10月)搜索相关文献27篇，ACP journal club (2012年9月) 16篇，CNKI (1998年1月至2012年10月) 29篇，并利用搜索引擎——谷歌学术搜索(2012年10月)互联网搜索并排除交叉文献237篇。通过两个副主任医生二次检索，共得出有关晚期胃癌手术和新辅助化疗时机的系统评价6篇，临床对照研究病例756例。未检索到单一化疗和生存率关系的高质量文献。检索并阅读文献共用时约50 h。</p></sec><sec id="s6_4"><title>4.4. 证据评价</title><p>Meta分析为回顾性研究，研究对象异质性较大。但总体看，该分析纳入了1998至2012年的大量文献，样本量大、分析全面、包括与本例相近的老年患者，因此是该问题目前所能获得的最佳证据。有关晚期胃癌手术和新辅助化疗时机的系统评价6篇，其中4 [<xref ref-type="bibr" rid="hanspub.16048-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.16048-ref9">9</xref>] 篇Meta分析认为新辅助化疗能提高进展期胃癌的根治性手术率及生存率，2篇[<xref ref-type="bibr" rid="hanspub.16048-ref10">10</xref>] 认为新辅助化疗和单纯手术对晚期胃癌的根治性手术率及生存率无明显影响。结果见表1。</p></sec></sec><sec id="s7"><title>5. 应用证据</title><p>通过将两种治疗方案及其利弊与患者家属充分沟通。患者家属选择新辅助化疗后手术治疗方案，并签署治疗同意书。化疗方案为奥沙利铂+希罗达(Cape + OX)。具体剂量为奥沙利铂130 mg/m<sup>2</sup>一次/日，第1天；希罗达1250 mg/m<sup>2</sup>，两次/日，第1~14天，每三周为一疗程。通过一个疗程的化疗后，患者颈部肿大淋巴结消失(CR)，进食梗阻感缓解。后又行一疗程化疗方案。复查腹部增强CT及胃镜，病灶明显缩小(PR) (图1；图2)。于新辅助化疗结束后第7日在全麻下行剖腹探查术。手术中见肝脏、网膜、盆腔未及转移或种植灶；肿瘤位于贲门小弯侧，大小约3 &#215; 2 cm，距贲门口约3 cm，胃周未见明显肿大淋巴结，行根治性全胃切除术 + 食管空肠Roux-en-y吻合术。术后病理提示：1)“全胃”贲门小弯侧溃疡型腺癌，中分化，肿瘤大小3 &#215; 2 &#215; 0.6 cm，癌组织侵犯胃壁深肌层，找及小弯侧淋巴结16枚，未见癌组织转移。上、下切缘，另送“上、下切缘”及大网膜均未见癌组织累犯。2)“第2组淋巴结”未见癌转移0/1(-)。病理分期为T2N0M0。手术后患者恢复良好，无并发症发生，于术后14日出院。</p></sec><sec id="s8"><title>6. 后效评价</title><p>晚期胃癌是指术前不可切除及术后复发的胃癌，其中术前不可切除的晚期胃癌占全部胃癌的30% [<xref ref-type="bibr" rid="hanspub.16048-ref11">11</xref>] ，</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The Meta analysis showed that the new adjuvant chemotherapy and palliative operation resection rate and the 5-year survival rate in patients with advanced gastric cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >作者</th><th align="center" valign="middle"  rowspan="2"  >时间</th><th align="center" valign="middle"  colspan="4"  >新辅助化疗组和姑息手术组相比</th></tr></thead><tr><td align="center" valign="middle" >手术切除率</td><td align="center" valign="middle" >(95%可信区间)</td><td align="center" valign="middle" >5年生存率</td><td align="center" valign="middle" >(95%可信区间)</td></tr><tr><td align="center" valign="middle" >王瑾，等[<xref ref-type="bibr" rid="hanspub.16048-ref7">7</xref>]</td><td align="center" valign="middle" >2004</td><td align="center" valign="middle" >OR 1.07</td><td align="center" valign="middle" >95% CI (0.60~1.48)</td><td align="center" valign="middle" >OR 1.92</td><td align="center" valign="middle" >95% CI (0.57~1.48)</td></tr><tr><td align="center" valign="middle" >Miyazaki et al. [<xref ref-type="bibr" rid="hanspub.16048-ref8">8</xref>]</td><td align="center" valign="middle" >2006</td><td align="center" valign="middle" >OR 1.61</td><td align="center" valign="middle" >95% CI (0.96~2.69)</td><td align="center" valign="middle" >OR 1.83</td><td align="center" valign="middle" >95% CI (1.43~2.33)</td></tr><tr><td align="center" valign="middle" >Nio et al. [<xref ref-type="bibr" rid="hanspub.16048-ref9">9</xref>]</td><td align="center" valign="middle" >2004</td><td align="center" valign="middle" >OR 1.42</td><td align="center" valign="middle" >95% CI (1.13~1.96)</td><td align="center" valign="middle" >OR 1.53</td><td align="center" valign="middle" >95% CI (1.05~2.06)</td></tr><tr><td align="center" valign="middle" >董平，等[<xref ref-type="bibr" rid="hanspub.16048-ref10">10</xref>]</td><td align="center" valign="middle" >2009</td><td align="center" valign="middle" >OR 1.02</td><td align="center" valign="middle" >95% CI (1.56~2.14)</td><td align="center" valign="middle" >OR 1.55</td><td align="center" valign="middle" >95% CI (1.38~2.12)</td></tr><tr><td align="center" valign="middle" >Cunningham et al. [<xref ref-type="bibr" rid="hanspub.16048-ref11">11</xref>]</td><td align="center" valign="middle" >2006</td><td align="center" valign="middle" >OR 0.63</td><td align="center" valign="middle" >95% CI (0.56~0.92)</td><td align="center" valign="middle" >OR 0.55</td><td align="center" valign="middle" >95% CI (0.30~0.48)</td></tr><tr><td align="center" valign="middle" >Boige et al. [<xref ref-type="bibr" rid="hanspub.16048-ref12">12</xref>]</td><td align="center" valign="middle" >2007</td><td align="center" valign="middle" >OR 1.57</td><td align="center" valign="middle" >95% CI (0.15~1.48)</td><td align="center" valign="middle" >OR 1.32</td><td align="center" valign="middle" >95% CI (0.60~1.72)</td></tr></tbody></table></table-wrap><p>表1. Meta分析显示新辅助化疗和姑息手术对晚期胃癌患者手术切除率和5年生存率的比较</p><p>图1. 化疗前胃镜病灶大小为3 &#215; 4 cm，治疗后为2 &#215; 3 cm</p><p>图2. 化疗前后腹部增强CT相同截面肿瘤大小对比</p><p>有文献报道，晚期胃癌如果不化疗的中位生存期只有3~4个月，通过化疗可延长4~7月的生存期[<xref ref-type="bibr" rid="hanspub.16048-ref12">12</xref>] 。该病例为晚期胃癌患者，手术前已发生淋巴结转移，通过检索MEDLINE、ACP journal club、CNKI、谷歌学术搜索等收索工具发现，4篇Meta分析认为新辅助化疗能提高进展期胃癌的根治性手术率及生存率，而2篇认为新辅助化疗和单纯手术对晚期胃癌的根治性手术率及生存率无明显影响。该患者通过循证学指导治疗，进行2次新辅助化疗，颈部转移淋巴结消失(CR)，腹部CT及胃镜检查提示肿瘤灶明显变小(PR)，获得了手术时机，手术后病理证实肿瘤侵犯胃壁深肌层，区域淋巴结均无癌转移。手术后未出现吻合口瘘，切口延期愈合等并发症，恢复顺利。晚期胃癌患者多存在梗阻，病灶出血等急需外科处理的情况，如姑息性手术解决此类情况，在手术中往往不能达到根治性手术目的[<xref ref-type="bibr" rid="hanspub.16048-ref13">13</xref>] 。该病例通过新辅助化疗降低肿瘤分期，较早阻止肿瘤细胞的扩散，为根治性手术争取了时机。通过该患者治疗，笔者体会如下：在决定有争议治疗方案时，通过全面评价文献证据和患者的病情来制定治疗方案，不仅注意了客观证据，还兼顾了患者的意愿，临床结局满意。</p><p>本研究Meta分析在搜集文献时可能存在因发表文献的语言造成偏倚[<xref ref-type="bibr" rid="hanspub.16048-ref14">14</xref>] ，本meta分析中检索语言只纳入中、英文，可能存在语言偏倚。同时还存在以下局限性：本研究共纳入6篇文献，其中五篇为欧美国家，一篇为中国，一些文献方法学质量较低，其分析重点是手术切除率和五年生存率的对比研究，但有的文献关于手术方式、化疗方案、病理分型等临床指标未纳入统计指标。以上因素亦可能导致检索偏倚[<xref ref-type="bibr" rid="hanspub.16048-ref15">15</xref>] ，如能在检索过程中考虑上述因素，得出的循证学证据将更加有说服力。</p></sec><sec id="s9"><title>文章引用</title><p>江平,王崇高,胡昇庠,张增岭,胡伟,桂德春. 1例晚期胃癌患者的循证治疗 Evidence-Based Treatment for 1 Case with Advanced Gastric Cancer Patients[J]. 亚洲肿瘤科病例研究, 2015, 04(03): 20-25. http://dx.doi.org/10.12677/ACRPO.2015.43004</p></sec><sec id="s10"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.16048-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Acín-Gándara, D., Pereira-Pérez, F., Castaño-Pascual, A., et al. (2012) Gastrointestinal stromal tumors: Diagnosis and treatment. Cirugía y Cirujanos, 80, 44-51.</mixed-citation></ref><ref id="hanspub.16048-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Nagasako, Y., Satoh, S., Isogaki, J., et al. (2012) Impact of anastomotic complications on outcome after laparoscopic gastrectomy for early gastric cancer. British Journal of Surgery, 99, 849-854. &lt;br&gt;http://dx.doi.org/10.1002/bjs.8730</mixed-citation></ref><ref id="hanspub.16048-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Lorenzen, S., Blank, S., Lordick, F., et al. (2012) Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Annals of Surgical Oncology, 19, 2119-2127. &lt;br&gt;http://dx.doi.org/10.1245/s10434-012-2254-1</mixed-citation></ref><ref id="hanspub.16048-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Bornschein, J., Rokkas, T., Selgrad, M., et al. (2011) Gastric cancer: Clinical aspects, epidemiology and molecular background. Helicobacter, 16, 45-52. &lt;br&gt;http://dx.doi.org/10.1111/j.1523-5378.2011.00880.x</mixed-citation></ref><ref id="hanspub.16048-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Blank, S., Bläker, H., Schaible, A., et al. (2012) Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbeck’s Archives of Surgery, 397, 45-55. 
&lt;br&gt;http://dx.doi.org/10.1007/s00423-011-0805-8</mixed-citation></ref><ref id="hanspub.16048-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Becker, K., Langer, R., Reim, D., et al. (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases. Annals of Surgery, 253, 934-939. 
&lt;br&gt;http://dx.doi.org/10.1097/SLA.0b013e318216f449</mixed-citation></ref><ref id="hanspub.16048-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">王瑾, 曲秀娟, 滕月娥, 等 (2013) 卡培他滨联合多西紫杉醇一线治疗晚期的临床观察. 临床肿瘤学杂志, 5, 442-444.</mixed-citation></ref><ref id="hanspub.16048-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Miyazaki, S., Kimura, Y., Danno, K., et al. (2011) S 1 treatment for elderly patients over 75 years with gastric cancer. Gan To Kagaku Ryoho, 38, 581-584.</mixed-citation></ref><ref id="hanspub.16048-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Nio, Y., Koike, M., Omori, H., et al. (2004) A randomized consent design trial of neoadjuvant chemotherapy with tegafurplusuracil (UFT) for gastric cancer—A single institute study. Anticancer Research, 24, 1879-1887.</mixed-citation></ref><ref id="hanspub.16048-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">董平, 顾钧, 陆建华, 等 (2009) 进展期胃癌新辅助化疗的临床研究. 浙江临床医学, 8, 807-808.</mixed-citation></ref><ref id="hanspub.16048-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Cunningham, D., Allum, W.H., Stenning, S.P., et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England Journal of Medicine, 355, 11-20. 
&lt;br&gt;http://dx.doi.org/10.1056/NEJMoa055531</mixed-citation></ref><ref id="hanspub.16048-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Boige, V., Pignon, J., Saint-Aubert, B., et al. (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE). American Society of Clinical Oncology, 25, 4510.</mixed-citation></ref><ref id="hanspub.16048-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Opitz, I., Kestenholz, P., Lardinois, D., et al. (2006) Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. European Journal Cardio-Thoracic Surgery, 29, 579-584. &lt;br&gt;http://dx.doi.org/10.1016/j.ejcts.2006.01.015</mixed-citation></ref><ref id="hanspub.16048-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Earle, C.C., Maroun, J. and Zuraw, L. (2002) Cancer Care Ontario Practice Guidelines Initiative Gastrointestinal Cancer Disease Site Group. Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline. Canadian Journal of Surgery, 45, 438-446.</mixed-citation></ref><ref id="hanspub.16048-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Stein, H.J., Feith, M. and Siewert, J.R. (2000) Cancer of the esophagogastric junction. Surgical Oncology, 9, 35-41. 
&lt;br&gt;http://dx.doi.org/10.1016/S0960-7404(00)00021-9</mixed-citation></ref></ref-list></back></article>